Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Astellas Pharma ( (JP:4503) ) has provided an announcement.
Astellas Pharma Inc. announced the continuation of its Performance-linked Stock Compensation and Stock Delivery Schemes for its executives, aimed at aligning management incentives with the company’s long-term value growth. These schemes, which include the BIP Trust for corporate executives and the ESOP Trust for group executives, are designed to enhance transparency and focus on increasing enterprise and shareholder value.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas Pharma Inc. is a pharmaceutical company that focuses on developing innovative therapies in various medical fields. The company is known for its commitment to improving the health of people around the world through its research and development efforts.
Average Trading Volume: 6,845,444
Technical Sentiment Signal: Sell
Current Market Cap: Yen2470.6B
For a thorough assessment of 4503 stock, go to TipRanks’ Stock Analysis page.